Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases

Shi,Zhenshan; Zhuang,Qian; You,Ruixiong; Li,Yueming; Li,Jian; Cao,Dairong

doi:10.3892/ol.2015.3891

Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases

Authors:
- Zhenshan Shi
- Qian Zhuang
- Ruixiong You
- Yueming Li
- Jian Li
- Dairong Cao
View Affiliations

Affiliations: Department of Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Pharmacy, Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: November 9, 2015 https://doi.org/10.3892/ol.2015.3891
Pages: 261-266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with renal medullary carcinoma (RMC) have a poor prognosis, usually due to late diagnosis. Computed tomography (CT) analysis may aid the differentiation between RMC and other types of renal cell carcinoma, in order to establish an accurate early diagnosis. There is a limited number of reports in the literature focusing on clinical and multi‑slice CT (MSCT) imaging findings of RMC. Consequently, the present study aimed to characterize the clinical and MSCT imaging features of RMC. For this purpose, the MSCT imaging findings of 6 patients with RMC were retrospectively studied. The patients were subjected to MSCT in order to investigate the characteristics of the tumors, including location, size, density, calcification, cystic or solid appearance, capsule sign, enhancement pattern and presence of retroperitoneal lymph node metastasis. The tumors in the current study presented a mean diameter of 7.48±3.25 cm, and were observed to be solitary and heterogeneous with necrotic components. The majority of the tumors did not contain calcifications (5/6); displayed an ill‑defined margin (4/6); were centered in the medulla; extended into the renal pelvis or peripelvic tissues (6/6); and did not exhibit a fibrous capsule. Localized caliectasis was observed in 3 of the 6 cases. The attenuation of the solid region of the RMC on unenhanced CT was equal to that of the renal cortex or medulla (42.3±2.7 vs. 40.7±3.6 and 41.2±3.9 Hounsfield units, respectively; P>0.05) while, on enhanced CT, the enhancement of the tumor was lower than that of the normal renal cortex and medulla during all phases (cortical phase, 52.6±4.8 vs. l99.5±9.7 and 72.7±6.4; medullary phase, 58.6±5.7 vs. 184.6±10.8 and 93.5±7.8; delayed phase, 56.8±6.1 vs. 175.7±8.5 and 96.5±7.9, respectively; P<0.05). In conclusion, RMC tends to be an infiltrative, ill‑defined heterogeneous mass with intratumoral necrosis, which arises from the renal medulla, and displays lower enhancement than the renal cortex and medulla during all phases on enhanced CT. Despite its rarity in adults, RMC should be included in a differential diagnosis when CT imaging reveals these features.

View Figures

View References

1	Davis CJ Jr, Mostofi FK and Sesterhenn IA: Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 19:1–11. 1995. View Article : Google Scholar : PubMed/NCBI
2	Skolarus TA, Serrano MF, Berger DA, Bullock TL, Yan Y, Humphrey PA and Kibel AS: The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 179:433–444. 2008. View Article : Google Scholar
3	Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
4	Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang X, Zhou M, Teh BT and Pavlovich CP: Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 106:62–65. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP and Ghavamian R: Renal medullary carcinoma: The Bronx experience. Urol. 70:878–882. 2007. View Article : Google Scholar : PubMed/NCBI
6	Sathyamoorthy K, Teo A and Atallah M: Renal medullary carcinoma in a patient with sickle-cell disease. Nat Clin Pract Urol. 3:279–283. 2006. View Article : Google Scholar : PubMed/NCBI
7	Simpson L, He X, Pins M, Huang X, Campbell SC, Yang XJ, Perlman EJ and Bergan RC: Renal medullary carcinoma and ABL gene amplification. J Urol. 173:1883–1888. 2005. View Article : Google Scholar : PubMed/NCBI
8	Khan A, Thomas N, Costello B, Jobling L, de Kretser D, Broadfield E and O'Shea S: Renal medullary carcinoma: Sonographic, computed tomography, magnetic resonance and angiographic findings. Eur J Radiol. 35:1–7. 2000. View Article : Google Scholar : PubMed/NCBI
9	Selby DM, Simon C, Foley JP, Thompson IM and Baddour RT: Renal medullary carcinoma: Can early diagnosis lead to long-term survival? J Urol. 163:12382000. View Article : Google Scholar : PubMed/NCBI
10	Blitman NM, Berkenblit RG, Rozenblit AM and Levin TL: Renal medullary carcinoma: CT and MRI features. AJR Am J Roentgenol. 185:268–272. 2005. View Article : Google Scholar : PubMed/NCBI
11	Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB and Perlman EJ: Renal medullary carcinoma: Clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 60:1083–1089. 2002. View Article : Google Scholar : PubMed/NCBI
12	Neville A and Hatem SF: Renal medullary carcinoma: Unsuspected diagnosis at stone protocol CT. Emerg Radiol. 14:245–247. 2007. View Article : Google Scholar : PubMed/NCBI
13	Steele EL and MacLennan GT: Renal medullary carcinoma. J Urol. 174:14492005. View Article : Google Scholar : PubMed/NCBI
14	Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, et al: EORTC Genito-Urinary Cancer Group: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 42:50–54. 2006. View Article : Google Scholar : PubMed/NCBI
15	Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C and Collette L: European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 19:2638–2646. 2001.PubMed/NCBI
16	Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
17	Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D and Loeb DM: Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 44:407–411. 2005. View Article : Google Scholar : PubMed/NCBI
18	Walsh A, Kelly DR, Vaid YN, Hilliard LM and Friedman GK: Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 55:1217–1220. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ronnen EA, Kondagunta GV and Motzer RJ: Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 24:e142006. View Article : Google Scholar : PubMed/NCBI
20	Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A and Dzik C: Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 5:e442013. View Article : Google Scholar : PubMed/NCBI
21	Stahlschmidt J, Cullinane C, Roberts P and Picton SV: Renal medullary carcinoma: Prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol. 33:551–557. 1999. View Article : Google Scholar : PubMed/NCBI
22	Walsh AM, Fiveash JB, Reddy AT and Friedman GK: Response to radiation in renal medullary carcinoma. Rare Tumors. 3:e322011. View Article : Google Scholar : PubMed/NCBI
23	Amin MB, Smith SC, Agaimy A, Argani P, Compérat EM, Delahunt B, Epstein JI, Eble JN, Grignon DJ, Hartmann A, et al: Collecting duct carcinoma versus renal medullary carcinoma: An appeal for nosologic and biological clarity. Am J Surg Pathol. 38:871–874. 2014. View Article : Google Scholar : PubMed/NCBI
24	Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M and Merino MJ: Renal medullary carcinoma: Molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 37:368–374. 2013. View Article : Google Scholar : PubMed/NCBI
25	Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC and Chintapalli KN: Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation. Radiographics. 26:1795–1810. 2006. View Article : Google Scholar : PubMed/NCBI
26	Blitman NM, Berkenblit RG, Rozenblit AM and Levin TL: Renal medullary carcinoma: CT and MRI features. AJR Am J Roentgenol. 185:268–272. 2005. View Article : Google Scholar : PubMed/NCBI
27	Yoshimitsu K, Irie H, Tajima T, Nishie A, Asayama Y, Hirakawa M, Nakayama T, Kakihara D and Honda H: MR imaging of renal cell carcinoma: Its role in determining cell type. Radiat Med. 22:371–376. 2004.PubMed/NCBI
28	Zhu Q, Zhu W, Wang Z and Wu J: Clinical and CT imaging features of mucinous tubular and spindle cell carcinoma. Chin Med J (Engl). 127:1278–1283. 2014.PubMed/NCBI
29	Strobel SL, Jasper WS, Gogate SA and Sharma HM: Primary carcinoma of the renal pelvis and ureter. Evaluation of clinical and pathologic features. Arch Pathol Lab Med. 108:697–700. 1984.PubMed/NCBI
30	Farmakis SG and Siegel MJ: Rhabdoid tumor: An aggressive renal medullary tumor of childhood. J Comput Assist Tomogr. 39:44–46. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zhang Z, Chen J, Zhou J, Liu Y, Feng Z, Tang L and Jin Y: Clinicopathological study and diagnosis of rhabdoid tumor of kidney combined with metanephric adenoma. Chin Med J (Engl). 127:4290–4291. 2014.PubMed/NCBI
32	Ganeshan D, Iyer R, Devine C, Bhosale P and Paulson E: Imaging of primary and secondary renal lymphoma. AJR Am J Roentgenol. 201:712–719. 2013. View Article : Google Scholar
33	Navas Martínez MC, Molina Escudero R, Soto Delgado M, Jiménez Romero ME and Jiménez Jiménez J: Bilateral primary renal lymphoma: Case report and bibliographic. Arch Esp Urol. 64:904–907. 2011.PubMed/NCBI
34	Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB and Perlman EJ: Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urol. 60:1083–1089. 2002. View Article : Google Scholar : PubMed/NCBI
35	Hindman N, Ngo L, Genega EM, Melamed J, Wei J, Braza JM, Rofsky NM and Pedrosa I: Angiomyolipoma with minimal fat: Can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology. 265:468–477. 2012. View Article : Google Scholar : PubMed/NCBI
36	Soto Delgdo M, Pedrero Márquez G, Arroyo Maestre JM and Beardo Villar P: Collecting duct carcinoma of the kidney. A contribution of 4 new cases. Arch Esp Urol. 67:714–717. 2014.PubMed/NCBI
37	Kwon KA, Oh SY, Kim HY, Kim HS, Lee HY, Kim TM, Lim HY, Lee NR, Lee HJ, Hong SH and Rha SY: Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. Cancer Res Treat. 46:141–147. 2014. View Article : Google Scholar : PubMed/NCBI